

# INDEX

Note: Page numbers followed by f and t refer to figures and tables, respectively.

- Abilities, identifying, 92–93
- Abstraction, in cognitive examination, 35
- Accident prevention, household, 101–5
- Acetylcholine
  - in Alzheimer's disease, 47
  - approaches to increase levels of, 209–13.
    - See also* Cholinesterase inhibitors
  - in dementia, 209
  - precursors, 209
- Activities
  - of daily living, 7
  - instrumental, 7
  - scheduling, 97, 300
  - structuring, 286
  - task breakdown, 290–91
- Acute care hospital, 87–88
- Acute psychiatric unit, 88
- Adult day care, 85–86
- Advance directives, 266–67
- Advocacy groups, 129
- Affect, in mental status examination, 26–27
- Affective disorder, Alzheimer-associated, 155–56
- Affective problems, 155–60
  - causes, 156–57
  - definition, 155–56
  - management, 157
- Age, dementia and, 10–12, 11f, 12f
- Aggression, 143–46
  - causes, 144
  - definition, 143–44
  - management, 145–46
  - urinary tract infection and, 202
- Agitation, 143–46
  - causes, 144
  - definition, 143–44
  - management, 145–46
- Agnosia
  - aggression/agitation in, 144
  - in Alzheimer's disease, 283
  - bathing problems in, 173
  - in cortical dementia, 2
  - dressing problems in, 182
  - eating problems in, 170
  - falling and walking/transferring difficulty in, 189
  - sexual problems in, 197
  - sleep problems in, 185
  - social withdrawal in, 165
  - suspiciousness, paranoia, and delusions in, 162
  - uncooperativeness and resistance to care in, 139–40, 142
  - wandering and pacing in, 147
  - yelling, calling out, and screaming in, 153
- AIDS-associated dementia, 65–67
- Akathisia
  - pacing and, 148
  - uncooperativeness and resistance to care and, 140
- Alcohol abuse, dementia related to, 73–74
- Alien hand syndrome, 48
- Allele, 270
- Alpha-2 macroglobulin gene, in Alzheimer's disease, 275
- Alzheimer's Association's Safe Return program, 101
- Alzheimer's disease
  - cholinesterase inhibitors for, 211
  - clinical picture, 44–45, 45t
  - depression in, 155–56, 213–14
  - in Down syndrome, 85, 274
  - drug therapy, 205–9, 206f
  - epidemiology, 46
  - four A's of, 282–83
  - functional assessment staging system, 7, 8t–9t, 242, 243t
  - genetic counseling and presymptomatic testing, 274–75
  - noncognitive behavioral and neuro-psychiatric symptoms, 44–45, 213–14
  - pathology and etiology, 46–47, 48f, 205, 206f, 282

- Alzheimer's disease (*continued*)  
 risk factors, 233  
 sleep problems in, 185  
 tips for caregiver, 283–93
- Amantadine, 227–28  
 for disinhibition-induced aggression, 146  
 for executive function disorder, 228–29  
 for social withdrawal and apathy, 167
- Amitriptyline  
 for depression in Alzheimer's disease, 213–14  
 side effects, 220t
- Amnesia  
 in Alzheimer's disease, 283  
 bathing problems in, 173  
 in cortical dementia, 2  
 dressing problems in, 182  
 eating problems in, 170  
 evaluation. *See* Memory testing  
 in fronto-temporal degeneration, 49  
 incontinence and toileting problems in, 177  
 in mild cognitive impairment, 237  
 in Parkinson's disease, 57–58  
 sexual problems in, 196  
 sleep problems in, 185  
 social withdrawal in, 165  
 suspiciousness, paranoia, and delusions in, 162  
 uncooperativeness and resistance to care in, 139  
 wandering and pacing in, 147
- Amyloid hypothesis, 205, 206f
- Amyloid precursor protein (APP) gene, in Alzheimer's disease, 47, 205, 274
- Amyotrophic lateral sclerosis, 49
- Anger, in caregivers, 118–19
- Anosagnosia, 29, 80
- Anti-inflammatory drugs, for Alzheimer's disease, 206–7
- Anticholinergic side effects  
 antidepressants, 219, 220t, 221  
 antipsychotic drugs, 216, 218t
- Anticipation, genetic, in Huntington disease, 62
- Anticonvulsants  
 for aggression/agitation, 145–46  
 in end-stage dementia, 248  
 for yelling, calling out, and screaming, 154
- Antidepressants, 219–22  
 for depressive delusions, 163  
 dosage and administration, 221  
 indications, 213–14, 219  
 selective serotonin reuptake inhibitor  
 for aggression/agitation, 145  
 for catastrophic reaction, 137  
 dosage and administration, 221  
 side effects, 220t  
 for social withdrawal and apathy, 167  
 for yelling, calling out, and screaming, 154
- side effects, 219–21, 220t  
 tricyclic, side effects, 220t, 221–22
- Antihistamines, 225
- Antioxidant therapy, for Alzheimer's disease, 207
- Antipsychotic drugs, 214–18  
 for aggression/agitation, 145–46  
 atypical, 214–15, 216, 217–18, 218t  
 for catastrophic reaction, 137  
 for delirium, 151  
 for delusions, 163–64  
 dosage and administration, 217–18  
 in end-stage dementia, 249  
 for hallucinations and illusions, 161  
 indications, 215–16  
 potency, 216  
 side effects, 216–17, 218t  
 typical, 214, 218, 218t  
 for yelling, calling out, and screaming, 154
- Anxiety, in dementia, 155
- Anxiolytics, 224–26
- Apathy, 164–68  
 causes, 165–66  
 definition, 164–65  
 incontinence and toileting problems in, 177  
 management, 166–68  
 in Parkinson's disease, 58  
 stimulants for, 229  
 versus uncooperativeness and resistance to care, 140
- Aphasia  
 aggression/agitation in, 144  
 in Alzheimer's disease, 283  
 bathing problems in, 173  
 catastrophic reaction in, 134  
 in cortical dementia, 2  
 fluent (Wernicke), 26  
 incontinence and toileting problems in, 177  
 nonfluent (Broca), 26  
 receptive, 26  
 sexual problems in, 196–97  
 social withdrawal in, 165  
 suspiciousness, paranoia, and delusions in, 162  
 uncooperativeness and resistance to care in, 139  
 wandering and pacing in, 147  
 yelling, calling out, and screaming in, 153
- Apnea, sleep, versus delirium, 150

- Apolipoprotein E gene (APOE)  
 in Alzheimer's disease, 47, 275  
 test for, 41t
- Appearance, in mental status examination, 24–25
- Apraxia  
 in Alzheimer's disease, 283  
 bathing problems in, 173  
 catastrophic reaction in, 134  
 in cortical dementia, 2  
 dressing problems in, 182  
 eating problems in, 170  
 evaluation for, 33, 34–35  
 falling and walking/transferring difficulty in, 189  
 incontinence and toileting problems in, 177  
 sexual problems in, 197  
 social withdrawal in, 165  
 uncooperativeness and resistance to care in, 139, 141–42  
 wandering and pacing in, 147
- Aripiprazole  
 for delusions and hallucinations, 215–16  
 dosage and administration, 218  
 side effects, 218t
- Arrhythmia, from antidepressants, 220t, 221
- Arsenic screen, in dementia evaluation, 41t
- Artificial feeding  
 in end-stage dementia, 244  
 ethical issues, 259–61
- Asset protection, 101
- Assisted living home, 86, 93. *See also* Placement
- Astrocytosis, in fronto-temporal degeneration, 50
- Asymmetric fronto-temporal degeneration, 49
- Attention, in Mini-Mental State Examination, 31–32
- Autopsy issues, 250
- Autosomal chromosomes, 270
- Autosomal dominant inheritance, 271
- Autosomal recessive inheritance, 271
- Backward training, for incontinence and toileting problems, 179
- Balance, poor  
 in Parkinson's disease, 57  
 in progressive supranuclear palsy, 59
- Basement effect, in Mini-Mental State Examination, 30
- Bathing problems, 172–76  
 causes, 173–74  
 definition, 172–73  
 management, 174–76  
 tips for caregiver, 285
- Bed bath, 175–76
- Behavior, in mental status examination, 24–25
- Behavior control, ethical issues, 254–55
- Behavioral disorders, noncognitive. *See* Noncognitive behavioral and neuro-psychiatric symptoms
- Benign senescent forgetfulness, 236
- Benzodiazepines, 225–26
- Beta-amyloid  
 in Alzheimer's disease, 46, 205  
 test for, 235  
 vaccine, 205
- Beta blockers, as mood stabilizers, 224
- Biological therapy  
 brain surgery, 229  
 bright light therapy, 229–30  
 electroconvulsive therapy, 230  
 pharmacologic, 201–29. *See also* Drug therapy
- Blood pressure  
 in Alzheimer's disease, 207–8  
 high, vasculopathy from, 71  
 low. *See* Hypotension
- Bovine spongiform encephalitis, 54, 232
- Bowel care, 176–81  
 in end-stage dementia, 246  
 preventive health care, 106–7, 172  
 tips for caregiver, 285–86
- Bradykinesia  
 in Parkinson's disease, 57  
 in progressive supranuclear palsy, 59
- Brain  
 infarction, vascular dementia from, 69, 71  
 infection, AIDS-associated dementia from, 65–67  
 lymphoma, AIDS-associated dementia from, 65, 67  
 surgery, in dementia patient, 229  
 traumatic injury, dementia after, 71–73  
 vascular disease. *See* Cerebrovascular disease
- Bright light therapy, for sleep problems, 188, 229–30
- Broca aphasia, 26
- Bromocriptine, 228  
 for executive function disorder, 228–29
- Bupropion  
 dosage and administration, 221  
 for executive function disorder, 228–29  
 side effects, 220t  
 for social withdrawal and apathy, 167
- Buspirone, 224, 226

- Caffeine, wandering and pacing from, 148
- CAG repeat  
 in dementia evaluation, 41t  
 in Huntington disease, 61–62, 276
- Calendar, 300
- Calling out. *See* Yelling, calling out, and screaming
- Capacity  
 determination, 261–65, 264t  
 ethical issues, 257–58  
 testamentary, 265
- Carbamazepine, 222–23
- Carbidopa, 227
- Cardiac arrhythmia, from antidepressants, 220t, 221
- Cardiopulmonary resuscitation (CPR), in terminal phase, 244
- Caregiver(s), 10  
 anger in, 118–19  
 communication among, 81  
 demoralization in, 112–13  
 dependency on, rating scales, 36  
 emotional problems, 110–15  
 family, 109–15  
 fatigue in, 114  
 grief in, 111–12  
 guilt in, 113–14  
 nonfamily, 115  
 supportive care for, 115–29. *See also* Caregiving interventions  
 tips for, 283–93
- Caregiver factors  
 in affective and mood problems, 157  
 in aggression/agitation, 144  
 in bathing problems, 174  
 in catastrophic reaction, 135  
 in delirium, 151  
 in dressing problems, 183  
 in driving problems, 194  
 in eating problems, 171  
 in falling and walking/transferring difficulty, 190  
 in hallucinations and illusions, 160  
 in incontinence and toileting problems, 178  
 in sexual problems, 197  
 in sleep problems, 186  
 in social withdrawal and apathy, 166  
 in suspiciousness, paranoia, and delusions, 163  
 in uncooperativeness and resistance to care, 141  
 in wandering and pacing, 148  
 in yelling, calling out, and screaming, 153
- Caregiving interventions, 119–29, 120t  
 addressing personal needs, 123–24  
 advocacy groups, 129  
 checklist, 299  
 coaching on how to approach patient, 121  
 education, 120–21  
 on genetics, 129  
 on myths and misunderstandings, 117  
 emotional support, 124–26  
 general approaches, 117–19  
 long-range planning, 122  
 placement, 127–28  
 problem-solving, 121  
 psychosocial, 295–96  
 resolving family conflicts, 126–27  
 respite, 122–23  
 substitute decision making, 123  
 support groups, 124–26  
 tips, 283–93
- Carotid endarterectomy, in dementia patient, 229
- Catastrophic reaction, 27, 133–37  
 aggression/agitation in, 145  
 causes, 134–35  
 definition, 133–34  
 documentation, 137  
 management, 135–37  
 tips for caregiver, 291–92  
 warning signs, 134
- Caudate nucleus, atrophy, in Huntington disease, 62
- Ceiling effect, in Mini-Mental State Examination, 30
- Cerebral spinal fluid pressure waves, in normal pressure hydrocephalus, 63–64
- Cerebrovascular disease  
 in Alzheimer's disease, 207–8  
 atypical antipsychotic drugs and, 216  
 in dementia, 69–71, 70t  
 preventive interventions, 232–33
- Ceruloplasmin, arylsulfatase electrophoresis, in dementia evaluation, 41t
- Checklist(s)  
 dementia symptoms, 22, 23t  
 supportive care, 298, 299
- Chloral hydrate, 225  
 side effects, 225  
 for sleep problems, 188
- Cholesterol, monitoring, in Alzheimer's disease, 208
- Cholinergic dysfunction  
 in Alzheimer's disease, 47  
 in Lewy Body dementia, 52–53
- Cholinergic receptors, stimulation, 209

- Cholinesterase inhibitors, 204, 210–13, 212f  
 dosage and administration, 211  
 indications, 211  
 for mild cognitive impairment, 238  
 side effects, 213
- Chromosomes, 270
- Citalopram  
 for depression in Alzheimer's disease, 213  
 dosage and administration, 221  
 side effects, 220t
- Clonazepam, 226
- Closed head injury, dementia after, 71
- Clothing  
 dressing problems. *See* Dressing problems  
 tugging at or removing, 182–83  
 underwear, with hip pads, 191
- Clozapine  
 for delusions and hallucinations, 215–16  
 side effects, 218t
- Co-morbid medical illnesses, 7, 10
- Coaching, on how to approach dementia patient, 121
- Cognitive examination, 29–36  
 expanded, 33–36  
 Mini-Mental State Examination, 30–33  
 patient refusal, 251–52  
 rating scales, 36
- Cognitive impairment  
 affective and mood problems in, 156–57  
 aggression/agitation in, 144  
 in Alzheimer's disease, 44, 282–83  
 apathy in, 165  
 bathing problems in, 173  
 catastrophic reaction in, 134–35  
 in definition of dementia, 2–3, 3t  
 delirium in, 150  
 depression-induced, 67–69  
 dressing problems in, 182  
 driving problems in, 193  
 drug therapy, 209–13, 212f  
 eating problems in, 170  
 evaluation for. *See* Cognitive examination  
 falling and walking/transferring difficulty in, 189  
 in fronto-temporal degeneration, 48  
 hallucinations and illusions in, 159  
 incontinence and toileting problems in, 177  
 in Lewy Body dementia, 51  
 mild, 236–38  
 versus noncognitive neuropsychiatric symptoms, 4–5  
 in Parkinson's disease, 57  
 sexual problems in, 196–97  
 sleep problems in, 185  
 social withdrawal in, 165  
 suspiciousness, paranoia, and delusions in, 162  
 uncooperativeness and resistance to care in, 139–40  
 wandering and pacing in, 147  
 yelling, calling out, and screaming in, 153
- Cognitive impairment, not dementia (CIND), 236–38
- Cognitive slowness, in progressive supranuclear palsy, 60
- Communication  
 among caregivers, 81  
 with dementia patient, 90–92, 93t, 286–87  
 of diagnosis and treatment options, 79–80  
 nonverbal, 92
- Competence, determination, 261–65, 264t
- Compulsions, in mental status examination, 28
- Computed tomography, in dementia evaluation, 41
- Concentration, in Mini-Mental State Examination, 31–32
- Consciousness, level of  
 in definition of dementia, 3  
 evaluation, 34
- Consensus building, 268
- Constipation  
 delirium from, 150  
 prevention, 246
- Cornell Scale for Depression in Dementia (CSDD), 36
- Cortical dementia, 43–55  
 in Alzheimer's disease, 44–47, 45t  
 definition, 2  
 in disseminated Lewy Body disease, 51–53, 53t  
 in fronto-temporal degeneration, 47–51, 50t  
 in prion disease, 53–55  
 versus subcortical dementia, 3, 4t
- Cortico-basal ganglionic degeneration, 49, 50
- Costs of dementia, 12
- Counseling  
 for dementia patient, 98  
 genetic. *See* Genetic counseling and presymptomatic testing
- Coup/contrecoup injury, dementia after, 73
- Creutzfeldt-Jakob disease, 53–55  
 variant, 54, 232
- Crisis preparation in dementia care, 83–84
- Cultural issues, in dementia care, 84–85

- Daily living  
 activities of, 7  
 dementia care in, 92–100
- Day program, 85–86
- Death  
 of dementia patient  
 family reactions, 249–50  
 predictors, 242, 243t  
 thoughts of, in mental status examination, 27
- Decision making  
 substitute, caregiver support, 123  
 in terminal phase of dementia, 242–44
- Decision-making capacity, determination, 261–65, 264t
- Deconditioning, falling due to, 189, 190
- Decubitus ulcers, prevention, 246
- Dehydration  
 delirium from, 150  
 in end-stage dementia, 248  
 pain question, 260
- Delay, in subcortical dementia, 2–3
- Delirium, 149–52  
 causes, 150–51  
 definition, 149–50  
 in dementia, 3–4  
 versus dementia, 3  
 management, 151–52  
 postoperative, 108
- Delusions, 161–64  
 in Alzheimer's disease, 44  
 antipsychotic drugs for, 215–16  
 causes, 162–63  
 definition, 161–62  
 depressive, 162  
 management, 163  
 uncooperativeness and resistance to care in, 140  
 dressing problems in, 182  
 eating problems in, 170  
 versus hallucinations, 159  
 in Lewy Body dementia, 51  
 management, 163–64  
 in mental status examination, 28  
 in Parkinson's disease, 58  
 tips for caregiver, 288–89  
 yelling, calling out, and screaming in, 153
- Dementia  
 classification, 2–3, 4t, 39–40  
 co-morbidity, 7, 10  
 cognitive symptoms. *See* Cognitive impairment  
 cortical pattern. *See* Cortical dementia  
 definition, 1–4, 3t, 282  
 diseases causing, 4, 5t  
 early diagnosis, benefits, 16, 235–36  
 evaluation. *See* Dementia evaluation  
 impairment and disability, 7, 8t–9t  
 mixed, 3  
 after traumatic brain injury, 71–73  
 in substance abuse, 73–74  
 noncognitive functional symptoms. *See* Noncognitive functional symptoms  
 noncognitive neuropsychiatric symptoms. *See* Noncognitive behavioral and neuropsychiatric symptoms  
 psychosocial intervention, 295–96  
 scope of problem, 10–12, 11f, 12f  
 subcortical pattern. *See* Subcortical dementia  
 terminal phase, 241–44  
 toxic, 73–74  
 vascular. *See* Vascular dementia
- Dementia care, 75–108  
 in adult with mental retardation, 85  
 complexities, 12–13  
 cultural and ethnic issues, 84–85  
 in day-to-day living, 92–100  
 goals, 75–77  
 good clinical practices, 82–84, 83t  
 guidelines for families, 279–93  
 health maintenance, 105–8  
 Johns Hopkins model, 281  
 principles, 75, 76t  
 safety-proofing, 101–4  
 setting, 81–82, 85–88, 93–94  
 acute care hospital, 87–88  
 acute psychiatric unit, 88  
 day program, 85–86  
 emergency department, 87  
 group and assisted living home, 86, 93  
 home, 93  
 hospice, 88  
 nursing home, 86–87, 93  
 supervision, 104–5, 105t  
 supportive, 89–108. *See also* Supportive care, for dementia patient  
 team approach, 81  
 in terminal phase, 241–50. *See also* Terminal care  
 treatment plan  
 attributes, 77–79, 78t  
 implementing, 79–82  
 in young, 84
- Dementia caregiver. *See* Caregiver(s)
- Dementia evaluation  
 differential diagnosis and workup, 5t, 37–42, 39f  
 family assessment, 37, 38t  
 formulation, 38–39

- indications, 15–16, 17t
- laboratory tests, 40–41, 40t, 41t
- neuropsychiatric assessment, 20–37
  - history, 20–22, 22f, 23t
  - mental status examination, 22–36, 25t.
    - See also* Mental status examination
    - in mild cognitive impairment, 237–38
  - patient refusal, 251–52
  - purposes, 17–18
  - settings, 18
  - stages, 18–19, 19t
  - supplemental scales, 36–37
  - symptom checklist, 22, 23t
- Demoralization, in caregivers, 112–13
- Demyelination, in multiple sclerosis, 64
- Dental health
  - in end-stage dementia, 247
  - maintenance, 106
- Denture care, 106
- Dependency on caregivers, rating scales, 36
- Depletion, in subcortical dementia, 2–3
- Depression
  - after traumatic brain injury, 72
  - in Alzheimer's disease, 45
  - delusions in, 162
    - management, 163
    - uncooperativeness and resistance to care in, 140
  - in dementia, 67–69, 155–56, 158, 209
  - dressing problems in, 182
  - drug therapy, 213–14. *See also* Anti-depressants
  - eating problems in, 170
  - electroconvulsive therapy, 230
  - in Huntington disease, 61
  - in multiple sclerosis, 64
  - in Parkinson's disease, 58
  - rating scales, 36
  - sleep problems in, 188
  - social withdrawal and apathy in, 165
  - suspiciousness and paranoia in, 162
  - tips for caregiver, 289–90
  - uncooperativeness and resistance to care in, 140
  - vascular, 68–69, 70, 213
  - wandering and pacing in, 147
  - yelling, calling out, and screaming in, 153
- Depression-induced cognitive impairment, 67–69
- Desipramine, side effects, 220t
- Dexadrine, for social withdrawal and apathy, 167
- Dignity, patient, in end-stage dementia, 247–48
- Diphenhydramine, 225
- Disabilities, in dementia, 7
- Disinhibition, 146
- Disrobing, 182–83
- Distraction
  - for affective and mood problems, 158
  - for catastrophic reaction, 136
  - for hallucinations and illusions, 160
- Diuretics, wandering and pacing from, 148
- Divalproex sodium, 222
- DNA testing, 271–72
- Donepezil, for Alzheimer's disease, 210–13, 212f
- L-Dopa, 227
  - for disinhibition-induced aggression, 146
  - for executive function disorder, 228–29
- Dopamine agonists, 227–28
  - aggression/agitation from, 144
- Dopamine loss, in Parkinson's disease, 58–59
- Down syndrome, Alzheimer's disease in, 85, 274
- Dressing problems, 181–84
  - causes, 182–83
  - definition, 181
  - management, 183–84
  - tips for caregiver, 284
- Drinking apraxia, 170
- Driving concerns, 192–96
  - causes, 193–94
  - definition, 192–93
  - ethical issues, 253–54
  - management, 194–96
  - tips for caregiver, 290
- Drug(s)
  - aggression/agitation from, 144
  - delirium from, 150
  - delusions from, 162
  - hallucinations from, 160
  - pacing from, 148
  - sexual problems from, 197
  - sleep problems from, 185, 186
  - social withdrawal and apathy from, 166
- Drug therapy, 201–29. *See also specific drugs, e.g.,* Antipsychotic drugs
  - administration of medications, 107, 287–88
  - for aggression/agitation, 145
  - for Alzheimer's dementia, 205–9, 206f
  - for behavior control, ethical issues, 254–55
  - for catastrophic reaction, 137
  - for cognitive symptomatology, 209–13, 212f
  - for delirium, 151
  - indications, 203

- Drug therapy (*continued*)  
 for noncognitive neuropsychiatric symptoms, 213–29  
 principles, 201–3  
 resistance to taking medications, 142  
 for social withdrawal and apathy, 167  
 for uncooperativeness and resistance to care, 143  
 for underlying disease, 203–9  
 for yelling, calling out, and screaming, 154
- Durable power of attorney, 242, 266
- Dyskinesia  
 drug therapy, 227–28  
 tardive, from antipsychotic drugs, 217
- Dysmnnesia, in subcortical dementia, 2–3
- Dythymia, in dementia, 155
- Early diagnosis of dementia, benefits, 16, 235–36
- Eating problems, 169–72  
 causes, 170–71  
 definition, 169–70  
 in end-stage dementia, 245  
 ethical issues, 259–61  
 management, 171–72  
 tips for caregiver, 283–84
- Education, caregiver, 120–21  
 on genetics of dementia, 129  
 on myths and misunderstandings about dementia, 117
- Electroconvulsive therapy  
 for aggression/agitation, 146  
 for depression, 230
- Electroencephalography  
 in dementia evaluation, 41t  
 in prion dementia, 54
- Electrophoresis, 41t
- Elimination patterns, 176–81  
 in end-stage dementia, 246  
 preventive health care, 106–7, 172  
 tips for caregiver, 285–86
- Elopement, 146–47
- Embolic stroke, 71
- Emergency department, dementia care in, 87
- Emotional incontinence, 27
- Emotional problems  
 in caregivers, 110–15  
 in end-stage dementia, 249
- Emotional support  
 for caregivers, 124–26  
 for dementia patient, 98
- Encephalitis, bovine spongiform, 54, 232
- Encephalopathy, spongiform, in prion dementia, 55
- Environmental factors  
 in affective and mood problems, 157  
 in aggression/agitation, 144  
 in bathing problems, 174  
 in catastrophic reaction, 135  
 in delirium, 151  
 in dressing problems, 183  
 in driving problems, 194  
 in eating problems, 171  
 in falling and walking/transferring difficulty, 190, 191  
 in hallucinations and illusions, 160, 161  
 in incontinence and toileting problems, 178  
 in sexual problems, 197  
 in sleep problems, 186  
 in social withdrawal and apathy, 166  
 in suspiciousness, paranoia, and delusions, 163  
 in uncooperativeness and resistance to care, 140–41  
 in wandering and pacing, 148  
 in yelling, calling out, and screaming, 153
- Environmental stimulation, for social withdrawal and apathy, 166–67
- Epidemiology of dementia, 10–12, 11f, 12f
- Escitalopram, side effects, 220t
- Estrogen-replacement therapy, for Alzheimer's disease, 206
- Ethical issues, 251–61  
 driving problems, 253–54  
 general principles, 267–68  
 health decisions for incapacitated patient, 257–58  
 living alone, 252–53  
 lying to dementia patient, 255–57  
 medications and restraints to control behavior, 254–55  
 refusal of evaluation by memory impaired patient, 251–52  
 refusal to eat, 259–61
- Ethnic issues, in dementia care, 84–85
- Euphoria, in dementia, 155
- Euthymia, in dementia, 155
- Eutonia, in dementia of multiple sclerosis, 64–65
- Executive function, in cognitive examination, 35–36
- Executive function disorder  
 aggression/agitation in, 144  
 apathy in, 165  
 drug therapy, 222, 228–29  
 eating problems in, 170  
 in fronto-temporal degeneration, 48  
 sexual problems in, 197

- in subcortical dementia, 2–3
  - suspiciousness, paranoia, and delusions in, 162
  - yelling, calling out, and screaming in, 153
- Extrapyramidal side effects, antipsychotic drugs, 216, 218t
- Eye movement disorder, in progressive supranuclear palsy, 59–60
- Falls, 188–92
  - causes, 189–90
  - in Lewy Body dementia, 51
  - prevention, 190–92
  - risk factors, 188–89
- Family
  - assessment, in dementia evaluation, 37, 38t
  - dementia care guidelines, 279–93
- Family caregivers, 109–15. *See also* Care-giver(s)
- Family conference, 79, 118
- Family conflicts, resolving, 126–27
- Family history, in neuropsychiatric assessment, 20, 22f
- Family pedigree, 20, 22f
- FAST (Functional Assessment Staging of Alzheimer's Disease) system, 7, 8t–9t, 242, 243t
- Fatigue, in caregivers, 114
- Feeding problems, 169–72
  - causes, 170–71
  - definition, 169–70
  - in end-stage dementia, 245
  - ethical issues, 259–61
  - management, 171–72
- Feeding tube
  - in end-stage dementia, 244
  - ethical issues, 259–61
- Fever, in end-stage dementia, 244
- Fluent aphasia, 26
- Fluid(s)
  - intake
    - in end-stage dementia, 248
    - maintenance, 94–95, 172
  - loss. *See* Dehydration
- Fluoxetine
  - dosage and administration, 221
  - side effects, 220t
- Fluphenazine, side effects, 218t
- Foot care, preventive, 106
- Formulation, in dementia evaluation, 38–39
- Frontal lobe fronto-temporal degeneration, 49
- Frontal lobe injury
  - catastrophic reaction in, 134–35
  - yelling, calling out, and screaming in, 153
- Frontal-subcortical dementia, apathy in, 165
- Fronto-temporal degeneration, 47–51, 50t
  - clinical picture, 48–49, 50t
  - epidemiology, 49–50
  - pathology, 50–51
  - subtypes, 49
- Function
  - executive, in expanded cognitive examination, 35–36
  - maximizing, 92–93
  - visuospatial
    - in expanded cognitive examination, 34–35
    - in Mini-Mental State Examination, 33
- Functional Assessment Staging of Alzheimer's Disease (FAST) system, 7, 8t–9t, 242, 243t
- Functional impairment, 169–200
  - bathing problems, 172–76
  - dressing problems, 181–84
  - driving problems, 192–96
  - eating problems and weight loss, 169–72
  - executive. *See* Executive function disorder
  - falls and walking/transferring difficulty, 188–92
  - incontinence and toileting problems, 176–81
  - rating scales, 36
  - sexual problems, 196–200
  - sleep problems, 184–88
  - staging system, 7, 8t–9t, 242, 243t
  - types, 7
  - visuospatial, in Parkinson's disease, 58
- Gait ataxia, in normal pressure hydrocephalus, 62–63
- Gait disorders, falling in, 189
- Galantamine, for Alzheimer's disease, 210–13, 212f
- Gastrostomy tube
  - in end-stage dementia, 244
  - ethical issues, 259–61
- Genetic anticipation, in Huntington disease, 62
- Genetic counseling and presymptomatic testing
  - in Alzheimer's disease, 274–75
  - in dementia evaluation, 41t
  - in Huntington disease, 275–76
  - issues, 272–74
  - types of tests, 271–72
  - in vascular dementia, 276
- Genetics, 269–76
  - of Alzheimer's disease, 47
  - caregiver education on, 129

- Genetics (*continued*)  
 of fronto-temporal degeneration, 50  
 of Huntington disease, 61–62  
 primer, 270–72
- Genogram, 20, 22f
- Gerstman-Straussler-Scheinker syndrome, 53–55
- Ginkgo biloba, for Alzheimer's disease, 207
- Glossary of terms, 301–9
- Glucose, monitoring, in Alzheimer's disease, 208
- Go–No Go Test, 36
- Grasp reflex, uncooperativeness due to, 140, 142
- Grief  
 in caregivers, 111–12  
 in dementia patient, 155, 156–57
- Group home, 86, 93. *See also* Placement
- Guilt, in caregivers, 113–14
- Guns, safety considerations, 101
- Hallucinations, 159–61  
 in Alzheimer's disease, 44  
 antipsychotic drugs for, 215–16  
 causes, 159–60  
 definition, 159  
 versus delusions, 159  
 versus illusions, 159  
 in Lewy Body dementia, 51  
 management, 160–61  
 in mental status examination, 28  
 in progressive supranuclear palsy, 60  
 tips for caregiver, 288  
 uncooperativeness and resistance to care  
 in, 140  
 yelling, calling out, and screaming in, 153
- Haloperidol  
 dosage and administration, 218  
 side effects, 218t
- Head injury, traumatic, dementia after, 71–73
- Health care  
 coordination, 105–6  
 preventive, 106–7
- Health decisions for incapacitated patient,  
 ethical issues, 257–58
- Health maintenance, in dementia care, 105–8
- Heavy metal exposure, dementia related to,  
 41t, 74
- Hemorrhagic stroke, 71
- Hepatitis, from atypical antipsychotic drugs,  
 217
- Hip pads, underwear with, 191
- Hippocampal sclerosis, 49
- History, 20–22  
 family, 20, 22f  
 medical, 20–21  
 past neuropsychiatric, 21–22  
 personal, 20  
 premorbid personality, 21  
 present illness, 22, 23t  
 substance abuse, 20
- HIV (human immunodeficiency virus)  
 AIDS-associated dementia from, 65–67  
 test for, in dementia evaluation, 41t
- Hoarding, tips for caregiver, 292–93
- Home  
 dementia care in, 93  
 leaving patient alone in, 104–5, 105t  
 safety-proofing, 101–3
- Homicidal thoughts, in mental status  
 examination, 27
- Homocysteine, monitoring, in Alzheimer's  
 disease, 208
- Hope, caregiver need for, 117
- Hospice care, 88  
 certification formula, 242, 243t  
 in end-stage dementia, 243–44, 249
- Hospitalization  
 for aggression/agitation, 145  
 for pneumonia or sepsis, 245
- Human immunodeficiency virus (HIV)  
 AIDS-associated dementia from, 65–67  
 test for, in dementia evaluation, 41t
- Huntingtin protein, 62, 276
- Huntington disease  
 clinical picture, 60–61  
 epidemiology, 61  
 genetic counseling and presymptomatic  
 testing, 275–76  
 pathology and etiology, 61–62
- Huperzine-A, for Alzheimer's disease, 210
- Hydration. *See also* Dehydration  
 in end-stage dementia, 248  
 maintenance, 94–95, 172
- Hydrocephalus, normal pressure, 62–64
- Hydroxyprogesterone, for sexual problems,  
 199
- Hydroxyzine, 225
- Hygiene  
 basic, 106–7  
 sleep, 95–96, 186–87
- Hyperorality, 170
- Hypertension therapy, in Alzheimer's  
 disease, 207–8
- Hypertensive vasculopathy, 71
- Hypomania, in dementia, 156
- Hypotension, orthostatic, 190  
 from antidepressants, 220t  
 from antipsychotic drugs, 216, 218t
- Hypothyroidism, dementia and, 235

- Identification items, wearing, 102
- Illusions, 159–61
  - causes, 159–60
  - definition, 159
  - management, 160–61
  - in mental status examination, 28
- Imipramine, side effects, 220t
- Immunotherapy, for Alzheimer's disease, 205
- Implicit learning, 96
- Incidence of dementia, 11–12, 12f
- Incontinence, 176–81
  - causes, 177–78
  - definition, 176–77
  - emotional, 27
  - in end-stage dementia, 246
  - management, 178–81
  - in normal pressure hydrocephalus, 62
- Infection
  - brain, AIDS-associated dementia from, 65–67
  - delirium from, 150
  - urinary tract
    - aggression from, 202
    - delirium from, 150
    - incontinence and toileting problems from, 177–78
- Information resources, 79
- Inhalant abuse, dementia related to, 73–74
- Inheritance patterns, 271
- Insight
  - lack of, in dementia, 80
  - in mental status examination, 29
- Institutional settings, safety-proofing, 103–4
- Instrumental activities of daily living (IADLs), 7
- Inventory, taking, 291
- Irritability, in dementia, 155
  
- Johns Hopkins model of care for dementia, 281
- Judgment, in mental status examination, 29
  
- Karyotyping, 271
- Knowledge assessment, in cognitive examination, 35
  
- Labile mood, in dementia, 155
- Laboratory tests, in dementia evaluation, 40–41, 40t, 41t
- Language assessment, 32–33. *See also* Talk (speech)
- Late-life depression, treatment, 209
- Lead exposure, dementia related to, 41t, 74
- Learning, implicit, 96
  
- Leaving alone, versus supervision of dementia patient, 104–5, 105t
- Leg, restless, 187
- Legal issues, 261–67
  - advance directives, 266–67
  - determination of capacity or competence, 261–65, 264t
  - driving concerns, 194–95
  - durable power of attorney, 266
  - testamentary capacity, 265
- Leukoencephalopathy, vascular dementia from, 69
- Leuprolide, for sexual problems, 146, 199
- Level of consciousness
  - in definition of dementia, 3
  - evaluation, 34
- Lewy bodies, in Parkinson's disease, 59
- Lewy Body dementia
  - cholinesterase inhibitors for, 211
  - clinical picture, 51–52, 53t
  - epidemiology, 52
  - pathology, 52–53
- Limbic circuit injury, catastrophic reaction in, 135
- Lithium carbonate, 223–24
- Living alone, 93–94, 252–53
- Living will, 266
- Local resources, 82, 118
- Lorazepam, 226
  - in end-stage dementia, 249
- Lou Gehrig's disease, 49
- Lumbar puncture, in dementia evaluation, 41t
- Luria Hand-Sequencing Test, 36
- Lying, ethical issues, 255–57
- Lyme disease titer, in dementia evaluation, 41t
- Lymphoma, brain, AIDS-associated dementia from, 65, 67
  
- Mad cow disease, 54, 232
- Magnetic resonance imaging, in dementia evaluation, 41
- Malnutrition, delirium from, 150
- Mania
  - after traumatic brain injury, 72
  - in dementia, 156
  - dressing problems in, 182
  - eating problems in, 170
  - mood stabilizers for, 222–24
  - uncooperativeness and resistance to care in, 140
- Mass action principle
  - in traumatic brain injury, 73
  - in vascular dementia, 71
- Massage, in end-stage dementia, 246

- Masturbation, public, 198
- Medical disorders
- affective and mood problems in, 157
  - aggression/agitation in, 144
  - bathing problems in, 173
  - catastrophic reaction in, 135
  - co-morbid, 7, 10
  - delirium in, 150
  - dressing problems in, 182–83
  - driving problems in, 193
  - eating problems in, 170–71
  - falling and walking/transferring difficulty in, 189–90
  - hallucinations in, 159–60
  - incontinence and toileting problems in, 177–78
  - sexual problems in, 197
  - sleep problems in, 185–86
  - social withdrawal and apathy in, 165–66
  - suspiciousness, paranoia, and delusions in, 162
  - uncooperativeness and resistance to care in, 140
  - wandering and pacing in, 147–48
  - yelling, calling out, and screaming in, 153
- Medical history, in neuropsychiatric assessment, 20–21
- Medical interventions, in end-stage dementia, benefits and burdens, 244–45
- Medications. *See* Drug(s); Drug therapy
- Memantine, for Alzheimer's disease, 208–9
- Memory disorder. *See* Amnesia
- Memory testing
- in expanded cognitive examination, 34
  - in Mini-Mental State Examination, 30–31, 32
  - patient refusal, 251–52
- Mental status examination, 22–36, 25t
- appearance and behavior in, 24–25
  - cognition in, 29–36
  - insight and judgment in, 29
  - mood and affect in, 26–27
  - perception in, 28
  - resistance to, 22–24, 251–52
  - self-attitude in, 27
  - talk (speech) in, 25–26
  - thought content in, 28–29
  - thoughts of death, suicide, or homicide in, 27
  - vital sense in, 27
- Mentally retarded adult, dementia care, 85
- Mercury screen, in dementia evaluation, 41t
- Metals, heavy, dementia related to, 41t, 74
- Methylphenidate
- for executive function disorder, 229
  - for social withdrawal and apathy, 167
- Microtubule-associated proteins
- in fronto-temporal degeneration, 50–51
  - in progressive supranuclear palsy, 60
- Mild cognitive impairment (MCI), 236–38
- Mini-Mental State Examination, 30–33
- dementia evaluation need based on, 16
  - limitations, 30
  - Modified, 33
  - strengths, 30
- Mirtazapine
- dosage and administration, 221
  - side effects, 220t
- Misunderstandings, about dementia, 117
- Mixed dementia, 3
- after traumatic brain injury, 71–73
  - in substance abuse, 73–74
- Modafenil, for social withdrawal and apathy, 167
- Modified Mini-Mental State Examination, 33
- Monoamine oxidase inhibitors, side effects, 220t
- Mood, in mental status examination, 26–27
- Mood disorders, 155–60. *See also* Depression; Mania
- after traumatic brain injury, 72
  - causes, 156–57
  - definition, 155–56
  - dementia in, 67–69
  - management, 157
  - in multiple sclerosis, 64–65
- Mood stabilizers, 222–24
- for catastrophic reaction, 137
  - indications, 222
- Mood states, 155
- Mood syndromes, 155–56
- Motor disorders
- in AIDS-associated dementia, 66
  - in depression-induced cognitive impairment, 67–69
  - drug therapy, 227–28
  - in Huntington disease, 60–61
  - in normal pressure hydrocephalus, 62–63
- Motor neuron fronto-temporal degeneration, 49
- Motor slowness
- in Parkinson's disease, 57
  - in progressive supranuclear palsy, 59
- Motor vehicle bureau, notification of driving problems, 194–95, 254
- Mouth care
- in end-stage dementia, 247
  - maintenance, 106

- Multi-infarct dementia, 69–71, 70t
- Multifactorial inheritance, 271
- Multiple sclerosis, 64–65
- Muscle weakness, falling due to, 189, 190
- Myths, about dementia, 117
- Naming, in Mini-Mental State Examination, 32
- Negative predictive value, screening test, 234–35
- Neuritic plaques
  - in Alzheimer's disease, 46
  - in Lewy Body dementia, 52
- Neurofibrillary tangles, in Alzheimer's disease, 46
- Neuroleptic malignant syndrome, from atypical antipsychotic drugs, 217
- Neurologic symptoms, in Alzheimer's disease, 45
- Neuronal loss
  - in Alzheimer's disease, 46
  - in fronto-temporal degeneration, 50
  - in Lewy Body dementia, 53
  - in Parkinson's disease, 58–59
  - in progressive supranuclear palsy, 60
- Neuropsychiatric assessment, 20–37
  - history, 20–22, 22f, 23t
  - mental status examination, 22–36, 25t. *See also* Mental status examination
  - in mild cognitive impairment, 237–38
- Neuropsychiatric disorders. *See* Psychiatric disorders
- Neuropsychiatric history, past, 21–22
- Neuropsychiatric Inventory (NPI), 36–37
- Neuropsychiatric symptoms
  - cognitive. *See* Cognitive impairment
  - noncognitive. *See* Noncognitive behavioral and neuropsychiatric symptoms
- Neuropsychological testing, in dementia evaluation, 38–39
- Neurosyphilis, preventive interventions, 231–32
- NMDA receptor antagonists, for Alzheimer's disease, 208–9
- Noncognitive behavioral and neuropsychiatric symptoms, 4–7, 6t, 131–68. *See also* Psychiatric disorders
  - affective and mood problems, 155–60
  - after traumatic brain injury, 72
  - aggression/agitation, 143–46
  - in AIDS-associated dementia, 66
  - in Alzheimer's disease, 44–45, 213–14
  - catastrophic reactions, 133–37
  - delirium, 149–52
  - drug therapy, 213–29
  - etiology and pathogenesis, 6
  - 4D approach, 131–33, 132t
  - in fronto-temporal degeneration, 48
  - hallucinations and illusions, 159–61
  - in Huntington disease, 61
  - in Lewy Body dementia, 51
  - morbidity, 6–7
  - prevalence, 6
  - rating scales, 36–37
  - social withdrawal and apathy, 164–68
  - suspiciousness, paranoia, and delusions, 161–64
  - uncooperativeness and resistance to care, 138–43
  - in vascular dementia, 69–70
  - wandering and pacing, 146–49
  - yelling, calling out, and screaming, 152–55
- Noncognitive functional symptoms, 169–200
  - bathing problems, 172–76
  - dressing problems, 181–84
  - driving problems, 192–96
  - eating problems and weight loss, 169–72
  - falls and walking/transferring difficulty, 188–92
  - incontinence and toileting problems, 176–81
  - rating scales, 36
  - sexual problems, 196–200
  - sleep problems, 184–88
  - staging system, 7, 8t–9t, 242, 243t
  - types, 7
  - visuospatial, in Parkinson's disease, 58
- Nonfluent aphasia, 26
- Nonsteroidal anti-inflammatory drugs, for Alzheimer's disease, 206–7
- Nonverbal communication, 92
- Normal pressure hydrocephalus
  - clinical picture, 62–63
  - epidemiology, 63
  - pathology and etiology, 63–64
- Nortriptyline
  - dosage and administration, 221
  - side effects, 220t
  - for vascular depression, 213
- Nursing home. *See also* Placement
  - dementia care in, 86–87, 93
  - safety-proofing, 103–4
- Nutrition. *See also* Feeding problems
  - maintenance, 94–95
  - poor, delirium from, 150
- Nutritional supplements, 172

- Obsessions, in mental status examination, 28
- Occupational therapist, 93–94
- Olanzapine
  - dosage and administration, 218
  - side effects, 218t
- Opioids, in end-stage dementia, 249
- Opisthotonos, in progressive supranuclear palsy, 60
- Opportunistic brain infection, AIDS-associated dementia from, 65, 67
- Oral health
  - in end-stage dementia, 247
  - maintenance, 106
- Orientation, in Mini-Mental State Examination, 30
- Orthostatic hypotension, 190
  - from antidepressants, 220t
  - from antipsychotic drugs, 216, 218t
- Out-of-home placement. *See* Placement
- Oxygen supplementation, in end-stage dementia, 248
- Pacing, 146–49
  - causes, 147–48
  - definition, 146–47
  - management, 148–49
- Pain
  - catastrophic reaction and, 135
  - dehydration and, 260
  - in end-stage dementia, 249
  - uncooperativeness and resistance to care and, 140
  - wandering and pacing and, 147–48
  - yelling, calling out, and screaming and, 153, 154
- Pallilalic speech, 26
- Palsy, progressive supranuclear, 49, 50, 59–60
- Panic attack, 156
- Panic disorder
  - in dementia, 156
  - in multiple sclerosis, 64
- Paranoia, 161–64
  - causes, 162–63
  - definition, 161–62
  - management, 163–64
- Paraphasic speech, 26
- Parkinsonism
  - causes, 59
  - drug therapy, 227–28
  - in Lewy Body dementia, 51
- Parkinson's disease
  - clinical picture, 57–58
  - epidemiology, 58
  - pathology and etiology, 58–59
- Paroxetine
  - dosage and administration, 221
  - side effects, 220t
- Pellagra, preventive interventions, 232
- Penetrating head injury, dementia after, 71–72
- Perception, in mental status examination, 28
- Perphenazine
  - dosage and administration, 218
  - side effects, 218t
- Personal affairs, taking inventory, 291
- Personal history, in neuropsychiatric assessment, 20
- Personal needs, caregiver, 123–24
- Personality change
  - after traumatic brain injury, 72
  - in fronto-temporal degeneration, 48, 49
  - in vascular dementia, 70
- Phobias, in mental status examination, 28
- Physical restraints
  - in end-stage dementia, 248–49
  - ethical issues, 254–55
  - for prevention of falling, 191
- Pick's disease, 50
- Place orientation, in Mini-Mental State Examination, 30
- Placement, 99–100
  - caregiver support, 127–28
  - reasons for, 100t
- Planning
  - ability, assessment, 34–35
  - long-range, caregiver, 122
- Pneumonia, in end-stage dementia, 245
- Polymorphism
  - definition, 270
  - restriction fragment length, 272
- Positive predictive value, screening test, 234
- Positron emission tomography, in dementia evaluation, 41
- Postconcussion syndrome, after traumatic brain injury, 72
- Power of attorney, durable, 242, 266
- Praxis. *See also* Apraxia
  - in expanded cognitive examination, 34–35
  - in Mini-Mental State Examination, 33
- Prednisone, for Alzheimer's disease, 206–7
- Premorbid personality, in neuropsychiatric assessment, 21
- Presenillin-1 gene
  - in Alzheimer's disease, 47, 274
  - test for, in dementia evaluation, 41t
- Presenillin-2 gene, in Alzheimer's disease, 47, 274–75

- Present illness, in neuropsychiatric assessment, 22, 23t
- Prevalence of dementia, 10–11, 11f
- Prevention, accident, household, 101–5
- Preventive health care, 106–7
- Preventive interventions for dementia, 231–35
  - approaches, 233
  - examples, 231–33
  - recommendations, 238–39
  - screening test characteristics, 234–35
  - target groups, 234
- Primary prevention, 231
- Prion dementia
  - clinical picture, 53–54
  - epidemiology, 54–55
  - pathology, 54–55
- Prion (proteinous infectious particle)
  - protein, 55
- Problem solving
  - skill development, 121
  - trial-and-error, 83
- Procedures, surgical, for dementia patient, 107–8
- Progesterone, for sexual aggression, 146
- Progressive supranuclear palsy, 49, 50, 59–60
- Prosody, in communication with dementia patient, 90
- Pseudodementia, 68
- Psychiatric disorders
  - aggression/agitation in, 144
  - bathing problems in, 173
  - delirium in, 150
  - depression in, 157
  - dressng problems in, 182
  - driving problems in, 193
  - falling and walking/transferring difficulty in, 189
  - hallucinations and illusions in, 159
  - incontinence and toileting problems in, 177
  - sexual problems in, 197
  - sleep problems in, 185
  - social withdrawal and apathy in, 165
  - suspiciousness, paranoia, and delusions in, 162
  - uncooperativeness and resistance to care in, 140
  - wandering and pacing in, 147
  - yelling, calling out, and screaming in, 153
- Psychiatric units, acute, dementia care in, 88
- Psychogeriatric Dependency Rating Scale, 36
- Psychological symptoms, noncognitive. *See* Noncognitive behavioral and neuropsychiatric symptoms
- Psychosocial intervention, 295–96
- Psychotherapy, for dementia patient, 98
- Quetiapine
  - for delusions and hallucinations, 215–16
  - dosage and administration, 217
  - side effects, 218t
- Raphe nuclei, serotonin cell loss in, in progressive supranuclear palsy, 60
- Rash, from atypical antipsychotic drugs, 217
- Rating scales, in dementia evaluation, 36–37
- Receptive aphasia, 26
- Refusal
  - to eat, 259–61
  - of evaluation by memory impaired patient, 251–52
- Registration, in Mini-Mental State Examination, 30–31
- Relationship with dementia patient communication in, 90–92, 93t
  - establishing, 89–90
- Repetition, in Mini-Mental State Examination, 32–33
- Resistance
  - to care, 138–43
  - causes, 139–41
  - definition, 138–39
  - management, 141–43
  - to mental status examination, 22–24, 251–52
- Resources
  - information, 79
  - local, 82, 118
- Respite, for caregivers, 122–23
- Restless leg syndrome, 187
- Restraints
  - in end-stage dementia, 248–49
  - ethical issues, 254–55
  - for prevention of falling, 191
- Restriction fragment length polymorphism (RFLP) studies, 272
- Rigidity
  - in Parkinson's disease, 57
  - in progressive supranuclear palsy, 59
- Risperidone
  - dosage and administration, 218
  - side effects, 218t
- Rivastigmine, for Alzheimer's disease, 210–13, 212f
- Routines, establishing, 96–97
- Rummaging, tips for caregiver, 292–93

- Safety-proofing, 101–4
  - in home, 101–3
  - in institutional settings, 103–4
  - living alone and, 94
- Sclerosis
  - amyotrophic lateral, 49
  - hippocampal, 49
  - multiple, 64–65
- Screaming. *See* Yelling, calling out, and screaming
- Screening tests, characteristics, 234–35
- Secondary prevention, 231
- Sedation
  - from antidepressants, 220t, 221
  - from antipsychotic drugs, 216, 218t
- Sedative-hypnotics, 224–26
  - indications, 224–25
  - side effects, 225
  - for sleep problems, 187–88
  - for yelling, calling out, and screaming, 154
- Seizures
  - from atypical antipsychotic drugs, 217
  - in end-stage dementia, 248
- Selective serotonin reuptake inhibitors
  - for aggression/agitation, 145
  - for catastrophic reaction, 137
  - dosage and administration, 221
  - side effects, 220t
  - for social withdrawal and apathy, 167
  - for yelling, calling out, and screaming, 154
- Self-attitude, in mental status examination, 27
- Senile plaques
  - in Alzheimer's disease, 46
  - in Lewy Body dementia, 52
- Sensitivity, screening test, 234
- Sepsis, in end-stage dementia, 245
- Serial sevens, in Mini-Mental State Examination, 31
- Serotonergic side effects, antidepressants, 219, 220t
- Serotonin cell loss, in progressive supranuclear palsy, 60
- Serotonin reuptake inhibitors
  - for aggression/agitation, 145
  - for catastrophic reaction, 137
  - dosage and administration, 221
  - side effects, 220t
  - for social withdrawal and apathy, 167
  - for yelling, calling out, and screaming, 154
- Serotonin syndrome, 219
- Sertraline
  - for depression in Alzheimer's disease, 213
  - dosage and administration, 221
  - side effects, 220t
- Severe Impairment Rating Scale (SIRS), 36
- Sex chromosomes, 270
- Sex-linked inheritance, 271
- Sexual aggression, management, 146
- Sexual problems, 196–200
  - causes, 196–97
  - definition, 196
  - management, 198–200
- Shunt surgery
  - in dementia patient, 229
  - for normal pressure hydrocephalus, 63
- Signs and symptoms
  - checklist, 22, 23t
  - as indication for dementia evaluation, 16, 17t
- Single photon emission computed tomography, in dementia evaluation, 41
- Skin care
  - in end-stage dementia, 246
  - preventive, 106
- Skin rash, from atypical antipsychotic drugs, 217
- Sleep apnea, versus delirium, 150
- Sleep hygiene, 95–96, 186–87
- Sleep problems, 184–88
  - bright light therapy, 229–30
  - causes, 185–86
  - definition, 184–85
  - drug therapy, 224–26
  - management, 186–88
- Slit lamp examination, in dementia evaluation, 41t
- Slowness
  - cognitive, in progressive supranuclear palsy, 60
  - motor
    - in Parkinson's disease, 57
    - in progressive supranuclear palsy, 59
- Smoking, safety considerations, 101
- Social withdrawal, 164–68
  - causes, 165–66
  - definition, 164–65
  - management, 166–68
  - stimulants for, 229
- Specialist input, in dementia assessment, 18
- Specificity, screening test, 234
- Speech
  - in mental status examination, 25–26
  - pragmatics, in communication with dementia patient, 90
- Spongiform encephalitis, bovine, 54, 232
- Spongiform encephalopathy, in prion dementia, 55

- Steroids, aggression/agitation from, 144
- Stiffness, in Parkinson's disease, 57
- Stimulants
  - for disinhibition-induced aggression, 146
  - for executive function disorder, 229
  - for social withdrawal and apathy, 167
- Stimulus-bound behavior, eating problems
  - in, 170
- Stroke-related dementia, 69–71, 70t
- Subcortical dementia, 57–74
  - in cerebrovascular disease, 69–71, 70t
  - definition, 2–3
  - in HIV-AIDS, 65–67
  - in Huntington disease, 60–62
  - in mood disorders, 67–69
  - in multiple sclerosis, 64–65
  - in normal pressure hydrocephalus, 62–64
  - in Parkinson's disease, 57–59
  - in progressive supranuclear palsy, 59–60
- Substance abuse
  - dementia related to, 73–74
  - history, in neuropsychiatric assessment, 20
- Substantia nigra, dopamine loss in, in Parkinson's disease, 58–59
- Substitute decision making, caregiver support, 123
- Suicidal thoughts, in mental status examination, 27
- Supervision, in dementia care, 104–5, 105t
- Support groups, caregiver, 124–26
- Supported living situation. *See* Placement
- Supportive care
  - for caregivers, 115–29. *See also* Caregiving interventions
    - checklist, 299
    - general approaches, 117–19
    - interventions, 119–29, 120t
    - psychosocial, 295–96
  - for dementia patient, 89–108
    - accident prevention, 100–105
    - approach to patient, 89–92, 93t
    - checklist, 298
    - communication, 90–92, 93t
    - in day-to-day living, 92–100
    - emotional support, 98
    - establishing daily routine, 96–97
    - establishing relationship, 89–90
    - health care coordination, 105–6
    - health maintenance, 105–8
    - hygiene and preventive health care, 106–7
    - maximizing function and identifying abilities, 92–93
    - medication administration, 107
    - nutrition and hydration, 94–95
    - placement, 99–100, 100t
    - procedures/surgery, 107–8
    - safety-proofing, 101–4
    - sleep hygiene, 95–96, 186–87
    - successful activities, 97
    - supervision, 104–5, 105t
    - travel, 98–99
    - for family, in end-stage dementia, 249, 250
- Surgery, for dementia patient, 107–8
- Suspiciousness, 161–64
  - causes, 162–63
  - definition, 161–62
  - eating problems in, 170
  - management, 163–64
- Tacrine, 210
- Talk (speech)
  - in mental status examination, 25–26
  - pragmatics, in communication with dementia patient, 90
- Tardive dyskinesia, from antipsychotic drugs, 217
- Task breakdown, 290–91
- Tau protein
  - in fronto-temporal degeneration, 49, 50
  - test for, 235
- Team approach
  - to dementia care, 81
  - to evaluation of dementia, 18
- Temporal lobe injury, catastrophic reaction
  - in, 135
- Terminal care, 241–50
  - autopsy issues, 250
  - bowel care, 246
  - dehydration, 248
  - emotional upheaval, 249
  - family and patient wishes, 242–44
  - family reactions to death, 249–50
  - family supportive care, 249, 250
  - feeding problems, 245
  - hospice care, 243–44, 249
  - maintaining patient dignity, 247–48
  - medical interventions, benefits and burdens, 244–45
  - oral health, 247
  - predictors of death, 242, 243t
  - restraints, 248–49
  - seizures, 248
  - skin care, 246
- Tertiary prevention, 231
- Testamentary capacity, 265
- Thalamostriatal fronto-temporal degeneration, 49
- Thermoregulation, impaired, from antipsychotic drugs, 216

- Thiothixine, side effects, 218t
- Thought content, in mental status examination, 28–29
- Thoughts of death, suicide, or homicide, in mental status examination, 27
- Three-step command, in Mini-Mental State Examination, 33
- Thrombotic stroke, 71
- Time orientation, in Mini-Mental State Examination, 30
- Toileting problems, 176–81
  - in end-stage dementia, 246
  - preventive health care, 106–7, 172
  - tips for caregiver, 285–86
- Tolcapone, 228
- Toxic dementia, 73–74
- Trail Making Test, verbal form, 35–36
- Transferring difficulty, 188–92
- Tranylcypromine, side effects, 220t
- Traumatic brain injury, dementia after, 71–73
- Travel, with dementia patient, 98–99
- Trazodone
  - indications, 219
  - side effects, 220t
  - for sleep problems, 187–88
  - for yelling, calling out, and screaming, 154
- Treatment plan
  - attributes, 77–79, 78t
  - implementing, 79–82
- Tremor, in Parkinson's disease, 57
- Tricyclic antidepressants
  - cardiotoxicity, 221–22
  - side effects, 220t
- Truth-telling, ethical issues, 255–57
- Tube feeding
  - in end-stage dementia, 244
  - ethical issues, 259–61
- Ulcers, decubitus, prevention, 246
- Uncooperativeness, 138–43
  - causes, 139–41
  - definition, 138–39
  - management, 141–43
- Underwear, with hip pads, 191
- Urinary incontinence, 176–81
  - causes, 177–78
  - definition, 176–77
  - in end-stage dementia, 246
  - management, 178–81
  - in normal pressure hydrocephalus, 62
- Urinary tract infection
  - aggression from, 202
  - delirium from, 150
  - incontinence and toileting problems from, 177–78
- Vaccine, beta-amyloid, 205
- Vacuolization, in fronto-temporal degeneration, 50
- Vascular dementia, 69–71, 70t
  - cholinesterase inhibitors for, 211
  - genetic counseling and presymptomatic testing, 276
  - preventive interventions, 232–33
- Vascular depression, 68–69, 70, 213
- Vasculopathy, hypertensive, 71
- Venlafaxine
  - dosage and administration, 221
  - side effects, 220t
- Visuospatial function
  - in expanded cognitive examination, 34–35
  - in Mini-Mental State Examination, 33
  - in Parkinson's disease, 58
- Vital sense, in mental status examination, 27
- Vitamin B<sub>12</sub>, dementia and, 235
- Vitamin C, for Alzheimer's disease, 207
- Vitamin E, for Alzheimer's disease, 207
- Vocalizations. *See* Yelling, calling out, and screaming
- Walking problems, 188–92
- Wandering, 146–49
  - causes, 147–48
  - definition, 146–47
  - management, 148–49
- Wandering garden, 149
- Weakness, falling due to, 189, 190
- Weight loss, 169–72, 259–61
- Wernicke aphasia, 26
- Wernicke-Korsakoff syndrome, 74
- White matter loss, vascular dementia from, 69
- Will, living, 266
- Yelling, calling out, and screaming, 152–55
  - causes, 152–53
  - definition, 152
  - management, 153–55
- Young person, dementia care for, 84
- Zalepon, 226
  - for sleep problems, 188
- Zolpidem, 226
  - side effects, 225
  - for sleep problems, 188